We evaluated whether the prototype holder was adequate to complete an entire BAESD procedure. Results: A total of 34 lesions required BAESD for resection, including 4 lesions in the cecum, 15 in the ascending colon, 13 in the transverse colon, and 2 in the sigmoid

colon. The prototype holder was used in all of the BAESD procedures Bortezomib nmr (34/34) without relief by an assistant. The mean duration of the BAESDs was 120 ± 108 minutes. Conclusion: The prototype holder can take the place of an assistant during BAESD procedures eliminating Key Word(s): 1. ESD; 2. BAESD; 3. balloon-assisted endoscopic submucosal dissection; 4. overtube; 5. holder Presenting Author: SU JIN buy 3-Methyladenine HONG Additional

Authors: MYUNG SOO KANG, DAE YONG KIM, JAE PIL HAN, MOON HAN CHOI, HEE KYUNG KIM, BONG MIN KO, MOON SUNG LEE Corresponding Author: SU JIN HONG Affiliations: Soonchunhyang University College of Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University College of Medicine Objective: In order to know the long-term outcome after ESD in EGC, we analyzed the results and the clinical outcomes after ESD of

EGC according to the pathologic extent. Methods: The ESDs were performed in 309 EGCs of 280 patients. Among them, 228 patients, who had ESD for EGC were classified by pathological severity based on absolute indication (AI), expanded indication (EI) or beyond expanded indication (BEI). Results: The complete resection rates were 96.4% in AI-group, 78.7% in EI-group, and 41.2% in BEI-group (P = 0.000). The en bloc resection rates were 97.6% in AI-group, 87.4% in EI-group, and 86.3% in BEI-group (P = 0.023). The 5-year tumor recurrence rates were 1.8% in the AI-group, 1.5% in the EI-group and 15.4% in the Thymidine kinase BEI-group (P = 0.000). The 5-year disease-specific survival rates were 100% in the AI-group, 100% in the EI-group, and 97.4% in the BEI-group (P = 0.088). The 5-year disease-free survival rates were 98.2% in the AI-group, 98.5% in the EI-group, and 84.6% in the BEI-group (P = 0.000). Conclusion: ESD was effective and safe in the AI or EI-group but a comparatively high rate of recurrence resulted from performance of ESD in the BEI-group. ESD may be useful in EGC patients at high-risk for surgery. Key Word(s): 1. early gastric cancer; 2. endoscopic submucosal dissection; 3. expanded indication; 4. long-term; 5.